ClinicalTrials.gg
Active, not recruitingNCT03794635Updated Jan 7, 2026

An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer

An interventional study of Weekly 45 minute Sessions in Metastatic Cancer, Locally Advanced Cancer and Thoracic Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center — 13 open to participants now, 27 under way, 1 of them phase 3. Neoplasm Metastasis · Memorial Sloan Kettering Cancer Center.

Enrollment
19th of 50
45 · median 37
Started
2018
with 2 others
No phase
10 of 61
1 open now
Primary completion
2026-12
later than 4 of 26 live
Registered
41st of 61
by date

Among the 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center, this one is the 19th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2018, is one of 10 with no phase, reaches primary completion later than 4 of the 26 other live ones, and was the 41st registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

13 of the 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

This study will test an intervention to improve patients' and their caregivers' ability to manage difficult emotions and communicate about the patient's illness. There will be two versions of the intervention used for this study: a culturally tailored version for Latinx participants refined during Phase 1 of this study, and a version of the intervention that was not culturally tailored for Latinx patients and caregivers developed in previous work. The two interventions differ in minor content areas. We will use the culturally tailored intervention for Latinx participants and the non-tailored intervention for non-Latinx participants. This culturally sensitive intervention has the potential to reduce Latino/a patient and caregiver distress and improve patient and caregiver quality of life, shared understanding of the patient's illness, and patients' and caregivers' ability to discuss, identify, and document patients' treatment preferences. The intervention is designed to minimize burden to patients, caregivers, and healthcare institutions to allow for easy integration into clinical practice.

03

Conditions studied

  • Metastatic Cancer
  • Locally Advanced Cancer
  • Thoracic Cancer
  • Gynecologic Cancer
  • Genitourinary Cancer
  • Lymphoma

Keywords

  • Latina
  • Latino
  • Spanish
  • Caregiver
  • 18-530
  • Memorial Sloan Kettering Cancer Center
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Patients:

  • Self-identifies as Latino/a
  • Diagnosis of poor prognosis advanced cancer defined as: (1) locally advanced or cancer (i.e., thoracic, gynecological, genitourinary cancer, pancreatic or lymphoma) or (2) disease progression following at least treatment
  • Fluent in English or Spanish
  • Age 18 or older
  • Has a primary informal caregiver (as defined by an unpaid individual who provides the patient with emotional, physical, and/or practical support) who is willing and able to participate in the study
  • Score of \</= 10 on the Blessed Orientation-Memory-Concentration Test (BOMC)
  • To assess whether a prognostic discussion occurred, the oncologist must answer "Yes" to the following: "Have you discussed the any of the following with Mr./Mrs./Ms. [INSERT PATIENT"S NAME]: If his/her cancer is curable, if his/her cancer is terminal, or his/her : Yes/No Note: This question will be included in the email in which study staff request permission to contact the patient.
  • As per self-report, residency in New York or ability to complete sessions in New York to ensure that provision of TAC is covered by the professional licenses of TAC interventionists (i.e., social workers licensed in New York State) - AIMS 2 and 3 ONLY
  • Able to communicate over the phone for sessions
  • Willingness to be audio-recorded for assessments and study sessions

For Caregivers:

  • Is a primary informal caregiver (as defined by an unpaid individual who provides the patient with emotional, physical, and/or practical support) for a MSK patient
  • Fluent in English or Spanish
  • Age 18 or older
  • Score of \</= 10 on the Blessed Orientation-Memory-Concentration Test (BOMC)
  • As per self-report, residency in New York or ability to complete sessions in New York to ensure that provision of TAC is covered by the professional licenses of TAC interventionists (i.e., social workers licensed in New York State) - AIMS 2 and 3 ONLY
  • Able to communicate over the phone for sessions
  • Willingness to be audio-recorded for assessments and study sessions

Psychosocial expert eligibility requirements:

  • Current clinical practice and/or research with advanced cancer patients
  • A history of 5+ years working with advanced cancer patients. Experts across disciplines (e.g., social work, psychology) may be enrolled.
  • Fluent in English as self-reported by a fluency of "Very well"

Exclusion criteria

Exclusion Criteria:

For Patients

  • As judged by the consenting professional, treating physician or self-report, too weak or cognitively impaired to participate in the intervention and complete the assessments
  • Receiving hospice at the time of enrollment
  • Deemed inappropriate for the study by their treating physician
  • As per medical record or self-report, currently being treated for schizophrenia, substance use or dependence, and/or bi-polar disorder

For Caregivers:

  • As judged by the consenting professional, treating physician or self-report, too weak or cognitively impaired to participate in the intervention and complete the assessments
  • As per self-report, currently being treated for schizophrenia, substance use or dependence, and/or bi-polar disorder

Patient-Caregiver Dyads:

  • Both dyad members respond "b" or "d" on the item in Appendix K, "How would you describe your/the patient"s health status: a) Relatively healthy, b) Relatively healthy and terminally ill, c) Seriously ill but not terminally ill, or d) Seriously and terminally ill" and respond "months" on the item "When you think about your/the patient's , do you think in terms of months or years."
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Patients

    Latino/a advanced cancer patients

    Behavioral: Weekly 45 minute Sessions

  • Experimental
    Caregivers

    Caregivers of Latino/a advanced cancer patients

    Behavioral: Weekly 45 minute Sessions

Interventions

  • BehavioralWeekly 45 minute Sessions

    The current intervention consists of seven, weekly,45-minute sessions conducted over the telephone using the TAC manual workbook. MSK-approved platforms (such as Webex or Cisco Jabber) can be used for telephone calls in this study. There will be two versions of the intervention used for this study: 1. A culturally tailored version for Latinx participants refined during Phase 1 of this study (available in English and Spanish) 2. A version of the intervention that was not culturally tailored for Latinx patients and caregivers developed in previous work. The two interventions differ in minor content areas. The culturally tailored intervention for Latinx participants and the non-tailored intervention for non-Latinx participants will be used. Interventions will occur weekly with a plus three-week window. Characteristics of prognostic discussions between patients and caregivers and health providers will be assessed at baseline and post-intervention.

06

What researchers measure

Primary outcomes

  1. Feasibility of patient-caregiver communication-based intervention defined by participant enrollment

    Time frame: 3 months

  2. Feasibility of patient-caregiver communication-based intervention defined by participant retention

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2018 (actual). Primary completion is estimated for Dec 2026, 96 months after the start.

Of 295 non-industry interventional studies with no phase under Neoplasm Metastasis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 93. This study's planned 96 months is above that.

Counting every sponsor, half of 320 studies reached it within 54 months; a quarter within 28 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2018
First posted
Jan 7, 2019
StartActual
Dec 20, 2018
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03794635
Responsible party
Sponsor
First posted
Jan 7, 2019
Start date
Dec 20, 2018
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 7, 2026

Study contacts

Kelly Trevino, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion